Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial

5 Jan 2021

Abstract excerpt

Abstract Acute respiratory distress syndrome (ARDS) in COVID-19 is associated with high mortality. Mesenchymal stem cells are known to exert immunomodulatory and anti-inflammatory effects and could yield beneficial effects in COVID-19 ARDS. The objective of this study was to determine safety and explore efficacy of umbilical cord mesenchymal stem cell (UC-MSC) infusions in subjects with COVID-19 ARDS. A...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Congenital Diaphragmatic Hernia Studies
Share to Mesenchymal stem cell research
Share to Respiratory Support and Mechanisms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33400390
DOI: 10.1002/sctm.20-0472

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trialPMID 33400390Read ↗

The rationale of using mesenchymal stem cells in patients with COVID-19-related acute respiratory distress syndrome: What to expectSemantic proximity Read ↗

Human Umbilical Cord-Derived Mesenchymal Stem Cell Therapy in COVID-19 Patients: A Phase 1 Clinical TrialSemantic proximity Read ↗

The Potential Use of Mesenchymal Stem Cells and Their Derived Exosomes as Immunomodulatory Agents for COVID-19 PatientsSemantic proximity Read ↗

Mesenchymal Stem Cells in the Treatment of COVID-19, a Promising Future.Semantic proximity Read ↗

Combating COVID-19 with mesenchymal stem cell therapySemantic proximity Read ↗

In Vivo Effects of Mesenchymal Stromal Cells in Two Patients With Severe Acute Respiratory Distress SyndromeSemantic proximity Read ↗

Effectiveness and Safety of MSC Cell Therapies for Hospitalized Patients with COVID-19: A Systematic Review and Meta-AnalysisSemantic proximity Read ↗

Human Mesenchymal Stem Cells Treatment for Severe COVID-19: 1-Year Follow-Up Results of a Randomized, Double-Blind, Placebo-Controlled TrialSemantic proximity Read ↗

Mesenchymal stem cell-based therapy and exosomes in COVID-19: current trends and prospectsSemantic proximity Read ↗

Mesenchymal Stem Cells Impact on COVID-19 Patients Immune System, an Ex Vivo StudySemantic proximity Read ↗

MSC-derived exosomes carrying a cocktail of exogenous interfering RNAs an unprecedented therapy in era of COVID-19 outbreakSemantic proximity Read ↗

COVID-19 and its Therapeutics: Special Emphasis on Mesenchymal Stem Cells Based TherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.